Pharmaceuticals, Biotechnology and Life Sciences
The company reported a net loss of $8.2 million, or $0.47 per share, for the three months ended March 31, 2020, compared to a net loss of $4.9 million, or $0.52 per share, for the same period in 2019. The company had $11.8 million in cash and cash equivalents as of March 31, 2020.
These data support the potential of our HPK1 inhibitor to alter the tumor microenvironment to halt cancer’s immune evasion, which we think could be a powerful tool in today’s immuno-oncology arsenal.
Pfizer’s 20vPnC vaccine candidate in Pahse 3 study showed responses elicited by 20vPnC for all 20 serotypes equivalent across all three lots, meeting the primary immunogenicity objective of the study.
Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response only 10 days after a single dose in mice.
Data reveal reductions in annual infections and warts, and sustained dose-dependent increases in neutrophil counts These and additional Phase 2…
The results of this study provide evidence of the potential benefit of MK-6482 and support further investigation into how this HIF-2α inhibitor could play a meaningful role for these patients
Schrödinger has reported a total revenue of $26.2 million and strong growth of 26% year-over-year, with record software revenue of $23.8 million, up 28% year-over-year, while it also raised $209.6 million in net proceeds through initial public offering.
MARLBOROUGH, Mass.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) said Wednesday in a press release that it has withdrawn the New Drug Applications…
Gossamer Bio has reported a net loss for the first quarter 2020, was $54.1 million, or $0.87 per share, compared to a net loss of $32.6 million, or $0.90 per share, for the same period in 2019, while cash, cash equivalents and marketable securities totaled $346 million as of March 31, 2020.
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.